Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction

Table 3 Change in echocardiographic parameters from the baseline to the study endpoint after the 24-week treatment with ARNI or ARB

	ARNI-continue group (n = 5)		p-value	ARB-switch group (n = 6)		p-value
	Baseline	24 weeks	p-value	Baseline	24 weeks	p-value
LVEDV index, mL/m²	62.3 ± 24.2	51.1 ± 19.1	0.465	71.2 ± 35.0	103.5 ± 6.8	0.138
LVESV index, mL/m²	37.5 ± 21.2	27.4 ± 14.1	0.465	41.3 ± 24.1	71.4 ± 8.8	0.043
LVEF, %	42.8 ± 11.4	44.8 ± 17.2	0.715	43.6 ± 12.2	30.6 ± 9.1	0.080
LAV index, mL/m²	42.3 ± 8.7	38.0 ± 9.7	0.109	46.2 ± 12.5	55.8 ± 11.9	0.225
LVM index, g/m²	138.7 ± 35.1	128.6 ± 8.2	0.715	140.0 ± 24.7	143.1 ± 11.7	0.686

Values are presented as mean ± standard deviation
ARNI angiotensin receptor-neprilysin inhibitor; ARB angiotensin II receptor blocker; LVEDV left ventricular end-diastolic volume; LVESV left ventricular end-systolic volume; LVEF left ventricular ejection fraction; LAV left atrial volume; LVM left ventricular mass

ISSN: 1471-2261